Silence Therapeutics


Silence Therapeutics is a biotechnology company that develops gene therapeutic technology based on RNA interference. They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters in Hammersmith, London.

Profile

The targeting, delivery and ongoing structural modification of sequences are the three platforms for Silence Therapeutics's RNAi therapeutic development. These three platforms are:
In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics. In 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.

Partnerships

Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as Mallinckrodt Pharmaceuticals, Takeda and Quark Pharmaceuticals.